Venous outflow obstruction plays an important role in the clinical expression of chronic venous disease. 1 The combination of reflux and obstruction gives the highest levels of venous hypertension and the most severe symptoms compared with either alone. 2, 3 Chronic obstruction of the iliac vein, which is the common outflow tract of the lower limb, results in severe symptoms because of poor compensation by collateral formation. 4, 5 Only 20% to 30% of thrombosed iliac veins treated by anticoagulation alone completely recanalize. Five years later, the remaining obstruction results in venous claudication in 44% and venous ulcer in 15% of patients. 6, 7 The recanalization process appears to be worse in the presence of an external compression, which has been reported in 80% of limbs with an acute iliofemoral deep vein thrombosis (DVT). 8, 9 The existence of iliac vein compressions and intraluminal webs is in itself more pathogenic than previously thought because they were considered a common finding of little clinical importance. This nonthrombotic iliac vein lesion (NIVL) is found as often as post-thrombotic obstruction in chronic venous disease involving the iliofemoral venous segment. It may occur in both the right and left lower limbs in both sexes at all ages and involve both the common and the external iliac veins. It is a major component of symptomatic primary disease. 10 Percutaneous endovenous stenting has emerged during the last decade as the method of choice to treat femoroiliocaval venous outflow obstruction due to chronic venous disease. It has replaced bypass surgery as the primary treatment. Stents have also been placed to relieve obstruction revealed after removal of acute iliofemoral thrombus or caused by malignant tumors or retroperitoneal thrombosis. 8, 9, 11, 12 Because the long-term outcome of the stenting procedure is related to the underlying etiology and the clinical situation, this study is limited to assess treatment in patients with chronic, nonmalignant obstructions. Stent placement started in earnest in our institution in 1997, and this experience has formed the basis for several reports on various aspects of venous stenting. [13] [14] [15] [16] [17] [18] Data sets are now available to perform long-term analysis of this group of patients; thus, the aim of this study is to evaluate procedure and long-term stent-related outcome, clinical outcome, and hemodynamic before and after results.
MATERIAL AND METHODS
From February 1997 to April 2005, 982 consecutive chronic nonmalignant obstructive lesions of the femoroiliocaval vein were treated in 870 patients. Limbs treated by thrombolysis before stenting are excluded. A timestamped electronic medical records program for patients with venous disease was specifically constructed to prospectively collect comprehensive standardized information on symptoms and physical findings in patients with venous disease.
The limbs were classified using the CEAP classification according to the Reporting Standards of International Society of Cardiovascular Surgery (ISCS)/Society for Vascular Surgery (SVS). 19, 20 The obstructive lesion was considered thrombotic when the patient had a known history of previous DVT or when post-thrombotic changes in the lower extremity were found on venogram, or duplex or intravascular ultrasound imaging (IVUS).
The following evaluations were performed before and after the intervention: ascending and transfemoral antegrade venography, 21, 22 duplex Doppler study with standardized compression, 23, 24 ambulatory dorsal foot venous pressure measurements, arm/foot pressure differential and dorsal foot venous hyperemia-induced pressure increase, 25 and air plethysmography (APG-1000; ACI Medical Inc, Sun Valley, Calif). 26 For a detailed description of the supporting studies see Appendix Table EI (online only) . Thrombophilia testing was performed in 683 patients, including levels of proteins C and S, antithrombin III, anticardiolipins immunoglobulin (Ig) M and IgG, and homocysteine, and the presence of lupus anticoagulant, factor V Leiden, homocysteine gene, and prothrombin gene mutation.
Intervention. The diagnosis of obstruction, indications for iliofemoral stenting, technical details of endovenous stenting, and perioperative anticoagulation treatment have been described previously. 13, 15, 16, 27 An ultrasound-guided access to the femoral vein was obtained and a sheath was inserted below the obstruction in symptomatic patients with suspicion of obstruction. After transfemoral venography, IVUS imaging was performed. The crosscut area of the stenosis was measured by IVUS and compared with the area of the normal vein below the stenosis, providing the percentage of stenosis. Stents were placed in limbs shown to have Ͼ50% morphologic stenosis by IVUS imaging. The transverse lumen area was obtained by IVUS imaging during the intervention before and after stenting.
The partially obstructed segment was balloon-dilated and stented under IVUS guidance to ensure that the entire lesion was covered (Figs 1 and 2 ). Occluded post-thrombotic veins required guidewire recanalization before stenting. Wallstents (Boston Scientific, Natick, Mass) were placed in 963 limbs (98%), and 19 limbs (2%) had nitinol stents placed. Stenting of a stenosis adjacent to the confluence of the common iliac veins using Wallstents required that the stent be placed well into the inferior vena cava (IVC) to avoid early restenosis. When two or more stents were inserted, the stents were overlapped by at least 1 cm to ensure adequate stent cover of the diseased vein without skipped areas. Procedure details were collected in a specifically designed database. The stenting was combined with procedures controlling superficial venous reflux (great saphenous vein [GSV] ablation/small saphenous vein [SSV] stripping/stab avulsions) in the same session in 197 limbs (see Appendix Table EII for details, online only). Compression and local ulcer therapy in use preoperatively was continued after intervention until healing. Prolonged use of the compression regimen was generally not encouraged because many considered it a quality-of-life issue. Noncompliant patients were not fitted with new stockings.
Follow-up. Clinical follow-up for treated limbs was at 6 weeks, 3 months, 9 months, and then annually. The study end point of legs with stasis ulceration was complete epithelialization. Primary nonhealing ulcers were marked as such and censored at 3 months. Any breakdown of an ulcer after healing was considered a recurrence. The degree of pain was evaluated perioperatively using a visual analog scale (VAS) from 0 to 10, wherein 10 is the most severe pain. 28 Swelling was assessed according to reporting standards as grade 0, absent; grade 1, pitting, not obvious; grade 2, visible ankle edema; and grade 3, massive, encompassing the entire leg. Patients were asked to complete the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ) assessing subjective pain, sleep disturbance, morale and social activities, and routine and strenuous physical activities prospectively before intervention and again at each postoperative visit. The CIVIQ form has a proven specificity and relevance to chronic venous disease. 29 The last available response was used in postoperative outcome analysis. Venous function studies were repeated on follow-up.
The degree of in-stent restenosis and patency was assessed by an antegrade transfemoral venogram. In-stent restenosis, if present, was assessed as the percentage diameter reduction of the patent lumen of the stent. An ascending venogram through a dorsal foot vein and duplex ultrasound imaging was also used to evaluate stent patency but not in-stent restenosis. The investigations were performed at 2 to 3 months, 9 months, and then annually after stenting.
Statistical analysis.
Individual data are given as median with range or mean Ϯ SD, unless otherwise indicated. Continuous variables were analyzed by t test or nonparametric Wilcoxon rank test for paired and unpaired data, depending on skewness, and the Fisher exact test for categoric variables. Primary, assisted primary (patency after preemptive intervention), and secondary patency (patency after intervention for occlusion) rates as defined by the reporting standards of the ISCVS/SVS 19 were calculated using survival analysis with the Kaplan-Meier method. Cumulative survival analysis was also used to analyze and compare recurrence of pain, swelling, and ulcer after the treatment. The log-rank test was used to compare cumulative curves Commercially available statistical programs Graph Pad Prism 3.0 (GraphPad Software, San Diego, Calif) and SAS 9.1 (SAS Institute, Inc, Cary, NC) were used for analysis. Results are reported using P values and either effect or odds ratio for continuous and categoric variables, respectively. A P Ͻ .05 was considered significant.
RESULTS
This study includes 982 limbs in 870 patients, of whom 112 patients (13%) had bilateral treatment with stents for obstruction of the femoroiliocaval vein. Median age was 54 years (range, 14 to 90 years). Female gender and left lower limb involvement were more than twice as common as male gender and right lower limb (female/male ratio, 2.6:1; left/right symptomatic limb ratio, 2.4:1). The CEAP clinical score was class 2 in 7% of limbs, class 3 in 47%, class 4 in 24%, class 5 in 5%, and class 6 in 17%. Thus, almost half of the patients had lower limb hyperpigmentation, dermatitis, lipodermatosclerosis, healed venous ulcer, or active ulcer. Most patients complained of limb pain (76%) and swelling (82%). Limbs of C class 2 were chosen for the procedure because of their associated pain. The etiology (E in CEAP) was primary (NIVL) in 518 limbs and secondary (postthrombotic) in 464.
Obstruction of the deep venous outflow with no reflux (P in CEAP) was found in 353 limbs (obstruction, 36%; reflux/obstruction, 64%). Guidewire recanalization was necessary in 62 occluded iliac veins in 464 post-thrombotic limbs (13%). In the 629 limbs with reflux and obstruction, reflux was found in 164 (26%) in the deep system alone, in 396 (63%) in the superficial system alone, and in 67 (11%) of limbs in combined systems (A in CEAP: deep veins, 53%; deep and superficial veins, 47%). Deep reflux was found in 24% of all limbs (236 of 982) and found to be axial (Kistner grade 3 to 4) in 75% (177 of 236). The median multisegment score was 1.8 (range, 1 to 7). Grade 2 to 4 obstruc- tion (Raju classification) was present in 26% of limbs, and an additional 36% had reduced phasicity of the femoral vein without pressure changes before stenting.
Post-stenting complications. The stenting procedures were performed with no mortality (Ͻ30 days). In the first 29 cases, two access-related complications occurred (7%) (1 retroperitoneal bleeding, 1 femoral artery injury requiring open repair). Ultrasound-guided access in the next 953 limbs limited cannulation complications to three femoral artery pseudoaneurysms, which were treated by thrombin injection, and an arteriovenous fistula, which closed spontaneously (0.004%). In one patient the guidewire became caught in the stent, which was pulled to the femoral vein and then openly removed. During the follow-up period, 47 thrombotic events occurred in 982 patients (5%).
All early thrombotic events (<30 days). Early thrombosis of the stented iliac vein occurred in 8 limbs, of the contralateral iliac vein in 4 limbs, at the femoral access site in 2 limbs, and was limited to the calf in 1 limb, for an overall rate of 1.5%. All 12 iliac thrombi occurred in postthrombotic limbs. All the contralateral DVTs were lysed successfully. Six limbs with stent occlusions had thrombolysis, which was successful in three. A Palma crossover bypass was performed in one patient. One patient with occluded stent had an immediate thrombectomy, but this rethrombosed after 3 weeks. One of the access-related femoropopliteal vein thrombi was successfully lysed. The calf DVT was treated by anticoagulation only.
All late thrombotic events. Occlusion of the stented iliofemoral vein occurred at a median of 13 months (range, 2 to 77 months) after stenting in 23 limbs, for an overall rate of 3%. In nine limbs, the occlusion was found at routine follow-up and treated only by anticoagulation. Early onset (Ͻ7 days) occurred in 13 limbs, and thrombolysis was attempted. This was successful in only four limbs, and the other limbs remained occluded. One patient had an open thrombectomy, which occluded in the postoperative period. Late acute thrombotic events occurred in the contralateral iliofemoral vein in seven limbs: one at the ipsilateral receiving femoral site of an old axillary vein transfer, and one nonocclusive thrombus was found attached to the proximal site of a stent in the IVC. The latter two limbs were treated only by anticoagulation. The IVC thrombus could not be detected at a later investigation. All limbs with contralateral proximal occlusions received thrombolysis, which was successful in five of seven limbs.
Contralateral iliac vein thrombosis. As already described, contralateral iliofemoral thrombosis occurred in 11 of 982 patients (1%) during the observation period. Three limbs were stented for NIVL and eight limbs for thrombotic obstructions. Nine of 11 limbs were successfully lysed.
Fig 2.
Chronic iliofemoral thrombotic stenosis before and after stenting. The stenting is carried into the common femoral vein to ensure an adequate inflow to prevent later occlusion.
Stent patency.
Venography or iliofemoral venous ultrasound imaging was performed one or several times in 610 limbs (62%) to verify patency at a mean of 30 months (range, 1 to 107 months) after stent placement. Ipsilateral early or late stent occlusion occurred in 31 limbs and was successfully lysed in seven; thus, 24 stents remained occluded. Overall primary, assisted-primary, and secondary cumulative patency rates at 72 months were 67%, 89% and 93%, respectively (Fig 3) . During the observation period, 149 secondary procedures were performed 1-97 months (mean, 19 months) after initial stenting to maintain patency (in-stent restenosis Ͼ50%) or to treat unresolved or recurrent symptoms. Additional stenting of stenosis above and the below previous stent was performed in 14 and 63 limbs, respectively; balloon angioplasty of in-stent restenosis in 56 limbs, and a combination of these procedures in 13 limbs. Stents were inserted in three limbs to bridge a stenotic skip area between previously inserted stents.
The stented limbs with NIVL fared significantly better (P Ͻ .0001) than did those with thrombotic disease, with primary, assisted-primary, and secondary cumulative patency rates of 79%, 100%, and 100%, and 57%, 80%, and 86% at 72 months, respectively (Fig 4) . The recanalized post-thrombotic limbs had the highest occlusion rates after stenting, with primary and secondary patency rates of 54% and 74% at 48 months ( Appendix Fig, online only) . The cumulative rate of severe in-stent restenosis (Ͼ50%) was assessed. The overall cumulative rate was 5% of limbs at 72 months and was higher in thrombotic limbs at 10% compared with 1% in NIVL limbs (P ϭ .0253; Fig 5) .
Factors associated with iliac vein stent thrombosis. During the observation time, 31 iliac stents occluded. All of the occluded limbs had thrombotic (secondary) obstruction. Thrombophilia test was available in 75% (454 of 610) of limbs included in the patency analysis and 38% (173 of 454) were positive. The test was positive for one or several factors in 23% (105 of 454) of post-thrombotic limbs compared with 14% (29 of 209) in NIVL limbs (P Ͻ .001, Fisher's Exact test). There was an over-representation of treated recanalized veins in the thrombosed stents (65% thrombosed vs 9% patent stents, P Ͻ .001).
The proportional contribution of different factors to stent occlusion was analyzed (Tables I and II) . The intervention side (left or right lower limb) and gender did not increase the risk of occlusion, but younger age appeared to do so. Of interest was that thrombophilia was more frequent in limbs with thrombotic disease but was not statistically associated with stent occlusion. Thrombotic etiology Cumulative primary, assisted-primary, and secondary patency rates for stented limbs with nonthrombotic iliac vein lesions (NIVL) and those with previous thrombosis. The lower numbers represent total limbs at risk for each time interval (all standard error of the mean Ͻ10%).
Fig 5.
Cumulative rates of severe in-stent restenosis (Ͼ50% narrowing) in the entire study group for limbs stented for postthrombotic lesions (thrombotic) and for limbs stented for obstruction caused by nonthrombotic iliac vein lesions. The lower numbers represent total limbs at risk for each time interval (all standard error of the mean Ͻ10%).
of the lesion and long lesions requiring several stents and extension into the common femoral vein were significantly associated with stent occlusion. The preoperative crosscut area of the stenosis, percentage stenosis on IVUS imaging, and occlusion requiring recanalization before stenting all reflect degree of stenosis and are significantly associated with thrombosis of the stent. Factors associated with in-stent restenosis. The proportional contribution of different factors to development of severe in-stent restenosis (Ն50%) was analyzed (Tables III and IV) . Factors associated with restenosis are similar to those associated with stent occlusion, except that age is not associated with restenosis. The presence of thrombotic disease is the dominating factor.
Clinical outcome. All 982 limbs, regardless of stent outcome, are included in the final analysis of the clinical outcome as an intent-to-treat study. Postinterventional clinical follow-up was a mean of 24 months (range, 1 month to 8.75 years), allowing cumulative long-term analysis. Information was available in 918 of 982 limbs (93%). Before treatment, 24% of limbs were completely pain-free, and 18% had no swelling. The preoperative and postoperative mean pain and swelling scores improved substantially: 3.7 (range, 0 to 9) and 0.8 (range, 0 to 10), and 1.7 (range, 0 to 3) and 0.8 (range, 0 to 3), respectively (P Ͻ .0001). The rate of limbs with severe pain (Ն5 on VAS) fell from 41% to 11% after intervention, and gross swelling (grade 3) in limbs decreased from 36% to 18%. As shown in Fig 6, cumulative freedom of pain and swelling were not statistically different whether or not an additional saphenous procedure was performed (P ϭ .8853 and P ϭ .5708, respectively). This graph is based on complete relief of swelling and pain (grade 0 swelling and 0 level of pain) and does not reflect partial improvement. After 5 years overall, 62% and 32% remained completely free of pain and swelling, respectively. The preoperative and postoperative mean pain and swelling scores in the subsets of limbs with NIVL and thrombotic obstruction improved to the same degree in both groups. When cumulative outcome curves of complete relief were compared at 5 years, there was no significant difference in pain outcome (thrombotic and NIVL limbs, 59% and 65%, respectively, P ϭ .7215). Limbs with thrombotic disease were, however, more frequently entirely free of swelling than NIVL limbs (39% and 24%, P ϭ .0041).
Ulcer healing. Healing of leg ulcers was followed up in 148 of 158 limbs for a mean 23 months (range, 1 to 99 months). In 47 limbs the ulcer did not heal. In the remaining 101 limbs, the ulcer healed and recurred in only eight limbs during the follow-up period. Thus, if healing of the ulcer was achieved after this intervention, ulcer recurrence was rare within the study period. The cumulative rate of ulcer healing at 5 years was 58% overall (50% with stent alone and 57% with additional procedure, P ϭ .9754; 62% for NIVL and 55% for thrombotic limbs, P ϭ .2819; Fig 7) .
Quality of life. The quality-of-life (QOL) questionnaire was introduced later in the study, explaining the shorter mean follow-up of 5 months (range, 1 to 79 months) and the smaller number of patients (n ϭ 381). There was significant improvement in all QOL categories after treatment (Table V) . The population of patients with no or little effect on QOL increased substantially (doubled in 3 of 5 categories). The CIVIQ score was the same in patients with thrombotic and NIVL limbs before stenting and decreased significantly in both groups of patients after the procedure. Adjunct procedures did not affect the QOL scores.
Hemodynamic outcome. To adequately assess the hemodynamic impact after successful stenting, 63 limbs with occluded stents or Ͼ50% in-stent stenosis were excluded from preintervention to postintervention hemodynamic comparison (919 limbs remaining). The hemodynamic results in the entire group and subsets of limbs with stenting combined with saphenous procedures and stenting alone are presented in Table VI . All limbs with adjunct correction of superficial reflux had a greater mean multisegment score (stent with added procedure and stenting alone, 2.3 Ϯ 1.6 and 1.4 Ϯ 1.7, respectively; P Ͻ .0001). The prevalence of axial deep reflux was the same in both groups of limbs (18%). After stenting, the improvement of venous filling time (VFT), venous filling index (VFI 90 ), and venous volume (VV) was associated with the adjunct procedures. The mean ambulatory venous pressure (AVP), however, was improved regardless of whether an adjunct procedure was performed, although the ejection fraction and residual volume fraction remained unchanged. The hand-foot pressure differential improved in limbs having stenting alone. Limbs with obstruction and no superficial or deep reflux were compared with those stented in the presence of reflux, which was left untreated (Table VII) . This comparison shows the true hemodynamic influence by stenting alone in limbs with and without reflux. Except for decrease of the hand-foot pressure differential in both groups, only ambulatory pressure was decreased in the nonrefluxing group after stenting.
Hemodynamics and etiology of obstruction. Comparison of the thrombotic with NIVL limbs revealed a greater multisegments score (2.2 Ϯ 1.9 and 1.1 Ϯ 1.3; P Ͻ .0001) and higher rate of deep axial reflux (32% and 6 %; P Ͻ .0001). The hemodynamic results in the two stented subgroups of primary and secondary etiology are given in Table VIII . Limbs with adjunct procedures to control reflux were excluded. After intervention, the hand-foot pressure differential improved in both sets of limbs. The ambulatory venous pressure, ejection fraction, and residual volume fraction improved in the NIVL limbs, indicating a global improvement of the hemodynamics and more efficient calf muscle pump. The hemodynamic effect of stenting was minimal in the thrombotic limbs, and residual volume fraction remained unchanged despite a decrease in ejection fraction.
Hemodynamics and axial reflux. Axial reflux due to primary (39 limbs) and thrombotic disease (138 limbs) was present in 177 of 982 limbs (18%). Except for improvement of the hand-foot pressure differential after stenting, all other parameters remained unchanged in this group of limbs after stenting. No enhancement of the retrograde reflux was observed as measured by VFT or VFI 90 , neither in limbs with primary nor secondary axial reflux.
Hemodynamics and clinical symptoms. Before stenting, ambulatory venous pressure was higher (42 Ϯ 19% and 58 Ϯ 21% drop), VFT shorter (10 Ϯ 6 seconds and 16 Ϯ 15 seconds), and VFI 90 greater (5.1 Ϯ 2.5 mL/s and 3.3 Ϯ 1.5 mL/s) in nonhealing limbs compared with healing limbs. Other hemodynamic results were the same in both groups. After stenting, all parameters remained unchanged in both limb groups when limbs with the adjunct procedures were excluded. As stated above, the cumulative rate for ulcer healing was the same whether or not an adjunct procedure was performed.
There was no difference in cumulative freedom of pain and swelling whether or not additional saphenous procedure was performed. When limbs with an adjunct procedure were excluded from the calculations, all except the hand-foot pressure differential remained unchanged. This pressure decreased significantly in both groups of limbs, with complete pain and swelling relief (1.2 Ϯ 1.3 to 0.7 Ϯ 1.0 [P ϭ .0087] and 1.6 Ϯ 1.7 to 0.8 Ϯ 1.4 [P ϭ .0147], respectively).
DISCUSSION
Stenting of the venous outflow obstruction of the lower extremities can be performed with low risk, long-term high patency rate, and a low rate of in-stent restenosis. It resulted in major symptom relief in patients with chronic venous disease, which was not consistently reflected in any substan- Although the literature has numerous small case reports, only a few larger series with acceptable short-term to mid-term follow-up have been published. Most of these reports mix limbs stented for chronic obstruction with those stented after clot removal. 30, 31 A recent retrospective analysis of 50 stented patients was reported. 32 Nearly half the patients had lysis before stenting, and more than 90% had thrombotic obstruction. Cumulative primary, assistedprimary, and secondary patency rates at 48 months were 58%, 71%, and 83%, respectively. Hartung et al 33 reported results of iliocaval stenting in 44 patients with chronic obstruction of primary, secondary, and congenital etiologies in 32, 10, and 2 limbs, respectively. Stenting was not preceded by thrombolysis. Overall cumulative primary, assisted-primary, and secondary patency rates at 36 to 60 months were 73%, 88%, and 90%, respectively, with intention to treat. Their results are comparable with those found in the present study.
Primary and secondary patency rates were obviously mainly related to the presence and severity of thrombotic disease. Further analysis of possible contributing factors confirmed that tight, long lesions of thrombotic etiology requiring multiple stents reaching caudad into the common femoral vein were of greatest risk to occlude. Even though the thrombotic state was such a high risk factor, the presence of thrombophilia in itself was not significantly associated with occlusion. The operation side and gender did not influence stent outcome, but younger age appeared to do so. Knipp et al 32 found that gender, recent trauma, and age younger than 40 years were predictive of decreased primary patency. The different finding may be explained by selection of patients, because half of the patients enrolled in that study had acute DVT. Only 10% of the limbs presented without current or previous DVT, possibly too few to detect the thrombotic state as being predictive.
In this study, the cumulative in-stent restenosis rate remained low in the long-term: 5% at 72 months. Risk 
Fig 6.
Cumulative sustained complete relief of pain and swelling after femoroiliocaval stenting in patients who had stent placement alone and in those with additional procedures. These curves do not reflect partial improvement only. Only limbs that had preoperative pain or swelling are shown. The lower numbers represent limbs at risk for each time interval (standard error of the mean Ͻ10%).
Fig 7.
Cumulative rate of limbs with healed ulcers in patients having stent placement alone and in those with additional procedures. Limbs with ulcers that never healed were marked as unhealed and censored at 3 months. The lower numbers represent limbs at risk for each time interval (standard error of the mean Ͻ10%).
factors for in-stent restenosis have been shown to be similar to those for stent occlusion, but it has not been conclusively proven that progressive in-stent restenosis results in occlusion.
14 Stent occlusion appears to be caused by a recurrent thrombotic event rather than slowly evolving narrowing of the stent. The cumulative rate of in-stent restenosis in this study was higher in thrombotic limbs (10%) than in nonthrombotic limbs (1%). Hartung et al 33 reported a 13% restenosis rate, but these authors appear to have included stenosis at the lower stent-vein border area, which is not considered true in-stent restenosis. The mechanism of development of in-stent restenosis is not yet known.
The present study spans a 9-year period and includes all patients during this period of time, including the initial "learning curve." Increasing experience throughout the time period has led to subsequent modification, which has improved outcome. Stent procedures performed early in the series sometimes needed later correction, explaining why some of the secondary procedures were performed. Skipped areas between inserted stents were abandoned early because they were prone to restenosis. In the first 25 patients, care was taken to avoid extension of the stent into the IVC by placing it slightly beyond the stenosis, even when the narrowing was at the iliocaval junction. About 40% of these stents developed proximal restenosis due to caudad migration when a braided Wallstent was used. 15 After this experience, all braided stents were inserted well into the IVC, thus preventing caudad migration. This is the explanation for the secondary cephalad stent extension. Even though the number of stents, length of stented area, and extension of the stent underneath the inguinal ligament into the common femoral vein are associated with stent occlusion and development of severe in-stent restenosis, the absolute numbers are low, and the stent length should not be limited for those reasons. Stents placed in the artery below the inguinal ligament often fracture and occlude. Fractures of venous stents placed in this position have never been reported, were not observed during this study, and are not related to venous stent occlusion at this site. Stent occlusions will be seen more frequently if the venous lesions are incompletely covered.
Careful IVUS investigations have taught us that the internal-external iliac vein confluence is stenotic in more than half of obstructed limbs with NIVL due to compression of the external iliac vein by the internal iliac artery diving into the pelvis. 10 Secondary stenting procedures for restenosis below the stent were due to a primarily overlooked compression lesion at this site or a predilection of this site for restenosis.
In the treatment of thrombotic obstruction, adequate inflow and outflow are crucial for long-term patency. The lower end of the stent is often placed just above the profundafemoral veins confluence in these limbs to ensure sufficient inflow. IVUS imaging has been shown to be superior to Venous stenting after ultrasound-guided venous access is performed with minimal risk. 30, 33, 35, 36 The overall rate of thrombotic events was 4.5%, similar to 5% reported by Hartung et al. 33 Thrombosis of the stented iliac veins occurred in 3% of all limbs and only in limbs treated for thrombotic obstruction. Stenting of primary iliac compression lesions with the present technique had very favorable long-term result, with no occlusions.
The extension of the stent into the IVC has raised concerns about relative obstruction to the venous outflow of the contralateral limb and subsequent thrombosis. The thrombosis rate was low (1%), however, and three-fourths of patients were stented for thrombotic obstruction. Probably because of acute onset of significant symptoms, the patients sought immediate treatment, and the success rate of thrombolysis or mechanical thrombectomy was high (82%). Thus, contralateral iliac vein thrombosis related to the IVC stent extension was generally benign and infrequent.
Chronic venous disease rarely threatens the survival of the limb or the patient, so the goal is to improve symptoms and the quality of life. The use of the VAS to measure the amount of pain has been properly validated and is useful. 28 The evaluation of swelling is semi-quantitative and less precise. Nevertheless, mean pain score and degree of swelling decreased significantly after stenting, and the proportion of patients with severe pain and swelling was significantly reduced. Complete relief of pain and swelling and healing of an ulcer are clear end points. Cumulative freedom from pain was better sustained than absence of swelling in the long term. The cumulative ulcer recurrence-free rate was 58% at 5 years. Long-term cumulative relief of pain and ulcer healing was the same in stented limbs with NIVL and thrombotic obstruction. The long-term complete relief of swelling was less in the NIVL limbs. The reason for this observation is unknown.
These end points capture different expressions of the chronic venous disease but do not provide information on the functional impact on the patient. For this purpose, generic and disease-specific questionnaires have been developed to assess the burden of disease on the individual patient as perceived by the patient. It has previously been shown that both primary chronic venous disease with "simple" varicose veins and disease with development of post-thrombotic stigmata significantly reduce QOL. [37] [38] [39] Specifically, previous iliofemoral DVT may cause clinically pertinent iliac outflow obstruction resulting in a marked compromise of QOL. 7 All five problem categories of the CIVIQ form used in this study improved significantly after stenting of both NIVL and thrombotic outflow obstructions. Chronic venous disease, regardless of etiology, affects QOL adversely, and stenting in patients with chronic venous outflow obstruction frequently markedly improved QOL. Significant improvement of Venous Clinical Severity and Venous Disability Scores has previously been reported by Hartung et al. 33 The hemodynamic changes using conventional methods were relatively minor compared with the clinical improvement. A few observations are noteworthy. Better results for reflux-related variables (VFT, VFI 90 , and VV) after treatment were observed only when adjunct saphenous procedures were combined with the stenting. In no subset of patients was a deterioration of venous reflux observed. An increase of reflux in a small group of postthrombotic limbs after stenting has been reported. 40 Axial deep reflux present before stenting did not, however, worsen the global reflux measurably after stenting in this study. The contention that the stenting of the proximal venous outflow obstruction would result in the loss of protection or buffering of retrograde reflux was not supported by these observations. Significant decrease of the mean hand-foot pressure differential in stented limbs occurred with and without remaining reflux and no adjunct procedures, and ambulatory venous pressure improved in most subsets of limbs. Although numerically small, these changes were statistically significant and indicated that the outflow obstruction was alleviated and the global hemodynamics improved after stenting. 16 Before stenting, limbs with thrombotic obstruction clearly had more extensive venous disease with more severe obstruction and reflux more frequently involving multiple systems and levels than limbs with NIVL. Despite this observation, stenting improved clinical symptoms and QOL substantially and similarly in both groups of patients. The positive clinical outcome was achieved with an improvement of the calf muscle pump function in the NIVL limbs, whereas the thrombotic limbs had no measurable hemodynamic improvement in these indicators. The hemodynamic response in patients who became completely free of pain and swelling or whose ulcers healed was no different than in those with residual pain or swelling or nonhealing ulcers. The lack of improvement of conventional hemodynamic test results underscores the poor understanding of the pathophysiology and the inability to accurately test hemodynamically significant venous obstruction. 
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